MLTX MoonLake Immunotherapeutics
Legal ·
The Peters suit names MoonLake and its chief executive, chief financial and chief scientific officers. The class period runs March 10, 2024 through September 29, 2025.
MoonLake drew $25.0 million under a Hercules loan totaling $500.0 million across six tranches. Most of the tranches still to come depend on Phase 3 results and FDA action for its lead drug, sonelokimab, and the company's 81% response figure comes from 26 patients with no comparison arm reported.
MoonLake's subsidiary, MoonLake Immunotherapeutics AG, borrowed the first tranche on March 31, 2025. Most further tranches depend on trial and FDA milestones, and the facility matures April 1, 2030.
MoonLake Immunotherapeutics is a clinical stage biotechnology company developing therapies for inflammatory skin and joint diseases. It is a single asset company focused on SLK, a tri-specific IL-17A and IL-17F inhibiting Nanobody exclusively licensed from MHKDG. SLK was discovered by Ablynx N.V., a Sanofi company, and previously studied by MHKDG and Avillion LLP under a 2017 co-development agreement. Its target diseases are hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), palmoplantar pustulosis (PPP) and psoriasis. In September 2025 the company reported primary endpoint data from the Phase 3 VELA-1 and VELA-2 trials in HS, where patients treated with SLK showed statistically significant improvement across all primary and key secondary endpoints. Enrollment in the Phase 3 IZAR-1 trial in PsA was completed in February 2026. A Phase 2 trial in axSpA reported that 81% of patients achieved an ASAS40 response at week 12. In a Phase 2 trial in PPP, the mean percent change from baseline in the PPPASI was 64% at week 16, and the FDA granted Fast Track designation for SLK in moderate-to-severe PPP.
| Product or program | What it is | Stage |
|---|---|---|
| SLK in hidradenitis suppurativa | IL-17A/F inhibiting Nanobody for moderate-to-severe HS | Phase 3 (VELA-1, VELA-2) |
| SLK in psoriatic arthritis | IL-17A/F inhibiting Nanobody for active PsA | Phase 3 (IZAR-1, IZAR-2) |
| SLK in axial spondyloarthritis | IL-17A/F inhibiting Nanobody for axSpA | Phase 2 (S-OLARIS) |
| SLK in palmoplantar pustulosis | IL-17A/F inhibiting Nanobody for PPP | Phase 2 (LEDA); Fast Track designation |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $202.9 million | $112.8 million |
| Net income (loss) | -$227.3 million | -$118.9 million |
| Cash from operations | -$196.0 million | -$116.6 million |
| Cash and equivalents | $334.5 million | $180.4 million |
| Short-term investments | $59.5 million | $267.6 million |
Our latest story on this, dated Aug 10, 2026: "MoonLake faces securities class action over sonelokimab; motion to dismiss pending". The story links the filing or release it is based on. Read the story.
MoonLake Immunotherapeutics trades under the ticker MLTX on NASDAQ.
MoonLake Immunotherapeutics is listed on NASDAQ.
The SEC Central Index Key (CIK) for MoonLake Immunotherapeutics is 1821586. Its filings are on SEC EDGAR.
85,106,685 shares as of 2026-08-01, per the cover page of its 10-Q filed 2026-08-10.
Our directory records MoonLake Immunotherapeutics under Switzerland.
Our directory classifies MoonLake Immunotherapeutics as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MoonLake Immunotherapeutics is KY61559X1045.
aibio.space lists MoonLake Immunotherapeutics among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
MoonLake Immunotherapeutics is a clinical stage biotechnology company developing therapies for inflammatory skin and joint diseases. It is a single asset company focused on SLK, a tri-specific IL-17A and IL-17F inhibiting Nanobody exclusively licensed from MHKDG.
SLK in hidradenitis suppurativa: IL-17A/F inhibiting Nanobody for moderate-to-severe HS Stage: Phase 3 (VELA-1, VELA-2).
SLK in psoriatic arthritis: IL-17A/F inhibiting Nanobody for active PsA Stage: Phase 3 (IZAR-1, IZAR-2).
MoonLake Immunotherapeutics reported a net loss of $227.3 million for the fiscal year ended Dec 31, 2025, and used $196.0 million of cash in operations, per its annual report to the SEC.
$202.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,2.03,5.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio